Notice of Extraordinary General Meeting
Released
Released
Announcement PDF
1 October 2025
All Registry communications to:
Automic Group
GPO Box 5193
Sydney NSW 2001
Telephone (free call within Australia): 1300 288 664
ASX Code: EXL
Email: hello@automicgroup.com.au
Dear Shareholder
General Meeting of Shareholders
Elixinol Wellness Limited ACN 621 479 794 (ASX: EXL or “the Company”), advises that Extraordinary General Meeting will be
held virtually via a video-conferencing facility on Friday, 31 October 2025 at 12.00pm (AEDT) (Meeting).
Notice of Meeting
The Notice of Meeting and Explanatory Memorandum (Notice) for the Meeting is available online and can be viewed and
downloaded by shareholders of the Company (Shareholders) from the Company’s website at https://elixinolwellness.com/
or the Company's ASX market announcements platform at www.asx.com.au (ASX: EXL). In the event it is necessary or
appropriate for the Company to make alternative arrangements for the Meeting, information will be provided to Shareholders
via the ASX and the Company’s website.
In accordance with recent amendments to the Corporations Act 2001 (Cth), and in line with our commitment to continually
look at ways of reducing our environmental impact, Shareholders will not be sent a hard copy of the Notice or Proxy Form
unless Shareholders have already notified the Company that they wish to receive documents such as the Notice and Proxy
Form in hard copy. To review your communications preferences or sign up to receive your Shareholder communications via
email, please update your details at https://investor.automic.com.au. If you have not yet registered, you will need your
Shareholder information including SRN/HIN details.
Voting
Online
by
Proxy
Lodge the Proxy Form online at https://investor.automic.com.au/#/loginsah by following the instructions:
1. Login to the Automic website using the holding details as shown on your holding statement.
scan the QR code
2. Click on ‘View Meetings’ – ‘Vote’.
below using your To use the online lodgment facility, Shareholders will need their holder number (Securityholder Reference
smartphone
Number (SRN) or Holder Identification Number (HIN)) as shown at the top of your holding statement.
Your proxy voting instruction must be received by 12.00pm (AEDT) on Wednesday, 29 October 2025
being not later than 48 hours before the commencement of the Meeting. Any Proxy Voting instructions
received after that time will not be valid for the scheduled Meeting.
For further information on the online proxy lodgment process, or if you require a hard copy Proxy Form, please contact the
Company’s Share Registry, Automic Registry Services (Automic), at hello@automicgroup.com.au or via phone on 1300 288
664 (within Australia) or +61 2 9698 5414 (overseas).
Shareholders can also contact the Company Secretary with any questions prior to the meeting via email at
melanie.leydin@vistra.com.
Yours sincerely,
Melanie Leydin
Company Secretary
Elixinol Wellness Limited
Elixinol Wellness Limited| ASX: EXL
ACN 621 479 794 | ABN 34 621 479 794
Suite 2, Level 11, 385 Bourke Street, Melbourne VIC 3000
info@elixinolwellness.com | www.elixinolwellness.com | @EXLWellness
NOTICE OF EXTRAORDINARY GENERAL MEETING AND EXPLANATORY STATEMENT
Date of Meeting:
Friday, 31 October 2025
Time of Meeting:
12.00pm (AEDT)
Place of Meeting:
Virtual meeting to be held online via a webinar conferencing facility at:
https://vistra.zoom.us/webinar/register/WN_BlQKZdX2QT-Virlh4WzQxQ
Elixinol Wellness Limited
ABN 34 621 479 794
NOTICE OF EXTRAORDINARY GENERAL MEETING
Notice is given that a meeting (EGM or Meeting) of shareholders (Shareholders) of Elixinol Wellness
Limited (Elixinol Wellness or the Company) will be held virtually via a webinar conferencing facility
at 12:00pm (AEDT) on Friday, 31 October 2025.
Shareholders are encouraged to submit their proxies as early as possible, and in any event, prior to
the cut-off date for proxy voting as set out in the Notice. To lodge your proxy, please follow the
directions on your personalised Proxy Form.
Shareholders attending the EGM virtually will be able to ask questions and the Company has made
provision for Shareholders who register their attendance before the start of the Meeting to also cast
their votes on the proposed Resolutions at the EGM.
The virtual Meeting can be attended using the following details:
When:
Topic:
Friday, 31 October 2025 at 12.00pm (AEDT)
EXL | Extraordinary General Meeting
Register in advance for the virtual Meeting:
https://vistra.zoom.us/webinar/register/WN_BlQKZdX2QT-Virlh4WzQxQ
After registering, you will receive a confirmation email containing information about joining the
Meeting. As noted previously, the Company strongly recommends its Shareholders to lodge a
directed proxy as soon as possible in advance of the Meeting even if they are planning to attend the
Meeting online. The Company will conduct a poll on each Resolution presented at the Meeting. The
Company will accept questions during the Meeting either by submitting a question through the Q&A
box located on screen or by raising the hand function also located on screen at which point the
Company will allow your question verbally.
The Company is happy to accept and answer questions submitted prior to the Meeting by email to
the Company Secretary, Melanie Leydin at melanie.leydin@vistra.com. The Company will address
relevant questions during the Meeting or by written response after the Meeting (subject to the
discretion of the Company not to respond to unreasonable and/or offensive questions).
Any Shareholders who wish to attend the EGM online should therefore monitor the Company’s
website and its ASX announcements for any updates about the Meeting. If it becomes necessary or
appropriate to make alternative arrangements for the holding or conducting of the Meeting, the
Company will make further information available through the ASX website at asx.com.au (ASX: EXL)
and on its website at https://www.elixinolwellness.com.
The Explanatory Statement accompanying, and which forms part of this Notice provides additional
information on matters to be considered at the EGM. The Explanatory Statement, Entitlement to
Attend and Vote section and Proxy Form are part of this Notice.
This Notice of Extraordinary General Meeting and Explanatory Statement should be read in its
entirety. If you are in doubt as to how to vote on the Resolutions, you should seek advice from your
accountant, solicitor or other professional adviser without delay.
The formal Resolutions proposed to be considered at the Meeting follow.
2
AGENDA
The Explanatory Statement and Proxy Form which accompany and form part of this Notice, includes defined
terms and describe in more detail the matters to be considered. Please consider this Notice, the Explanatory
Statement and Proxy Form in their entirety.
ORDINARY BUSINESS
Resolution 1: Ratification of Prior Issue of Tranche 1 Placement Shares
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That for the purpose of Listing Rule 7.4 and for all other purposes, Shareholders approve, ratify and confirm the
allotment and issue of 46,800,000 fully paid ordinary Shares in the Company on 12 September 2025 at an issue
price of $0.0135 (1.35 cents) per Share in relation to Tranche 1 of the Placement, to professional and sophisticated
investors, as described in the Explanatory Statement which accompanies and forms part of this Notice”.
Resolution 2: Approval to issue Tranche 2 Placement Shares
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, under and for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company
to issue 138,385,185 fully paid ordinary Shares in the Company at an issue price of $0.0135 (1.35 cents) per
Share to professional and sophisticated investors in relation to the Tranche 2 Placement as announced on 8
September 2025, on the terms and conditions set out in the Explanatory Statement which accompanies and forms
part of this Notice”.
Resolution 3: Approval to issue attaching options to Placement participants
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, under and for the purposes of Listing Rule 7.1, and for all other purposes, approval is given for the Company
to issue up to 185,185,185 Options in the Company to professional and sophisticated investors attaching to the
Shares issued under Tranche 1 and Tranche 2 of the Placement announced on 8 September 2025, on the terms
and conditions set out in the Explanatory Statement which accompanies and forms part of this Notice”.
Resolution 4: Approval to issue Lead Manager Options
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
"That subject to Shareholder approval of Resolution 2 and Resolution 3, under and in accordance with Listing
Rule 7.1 and for all other purposes, the Shareholders approve the issue of 35,000,000 new Options to Peak Asset
Management Pty Ltd AFSL 296877 (and/or its nominee(s)) on the terms and conditions set out in the Explanatory
Statement".
BY ORDER OF THE BOARD
Melanie Leydin
Company Secretary
1 October 2025
3
Notes
1. Entire Notice
The details of the resolutions contained in the Explanatory Statement accompanying this Notice should be read together with, and form part
of, this Notice.
2. Record Date
The Company has determined that for the purposes of the Extraordinary General Meeting, shares will be taken to be held by the persons who
are registered as holding the shares at 7:00pm on the date 48 hours before the date of the Extraordinary General Meeting, this is no later than
7:00pm (AEDT) on Wednesday, 29 October 2025. Only those persons will be entitled to vote at the Extraordinary General Meeting and
transfers registered after that time will be disregarded in determining entitlements to attend and vote at the Extraordinary General Meeting.
3. Voting
Each of the Resolutions proposed at the Meeting will be decided on a poll. On a poll, Shareholders have one vote for every Share held.
4. Proxies
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
Votes at the Extraordinary General Meeting may be given personally or by proxy, attorney or representative.
Each Shareholder has a right to appoint one or two proxies.
A proxy need not be a Shareholder of the Company.
If a Shareholder is a company it must execute under its common seal or otherwise in accordance with its constitution or the Corporations
Act.
Where a Shareholder is entitled to cast two or more votes, the Shareholder may appoint two proxies and may specify the proportion or
number of votes each proxy is appointed to exercise.
If a Shareholder appoints two proxies, and the appointment does not specify the proportion or number of the Shareholder’s votes, each
proxy may exercise half of the votes.
A proxy form must be signed by the Shareholder or their attorney who has not received any notice of revocation of the authority. Proxies
given by corporations must be signed in accordance with corporation’s constitution and Corporations Act.
If you sign the Proxy Form and do not appoint a proxy, you will have appointed the Chair as your proxy.
To be effective, Proxy Forms must be received by the Company’s share registry (Automic Pty Ltd) no later than 48 hours before the
commencement of the Extraordinary General Meeting this is no later than 12:00pm (AEDT) on Wednesday, 29 October 2025. Any
proxy received after that time will not be valid for the scheduled Meeting.
5. Corporate Representative
Any corporate Shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that person with
a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company’s representative. The
authority may be sent to the Company and/or share registry in advance of the Meeting or handed in at the Meeting (in person) when registering
as a corporate representative.
6. Undirected Proxies
Subject to the restrictions set out in Notes 7 and 8 below, the Chair will vote undirected proxies in FAVOUR of each Resolution. In exceptional
circumstances, the Chair may change their voting intention on a Resolution, in which case an ASX announcement will be made. Shareholders
may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
7. Voting Exclusion Statement
Resolution 1
The Company will disregard any votes cast in favour of this resolution by or on behalf of any person/entity, or any associates of those
persons/entities, who participated in the issue of securities securities, or is a counterparty to the agreement being approved, addressed by
this resolution.
However, this does not apply to a vote cast in favour of this resolution by:
(a)
a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or
attorney to vote on the resolution in that way; or
(b)
the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given
to the chair to vote on the resolution as the Chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate
of a person excluded from voting, on the resolution; and
(ii)
the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Resolutions 2 and 3
The Company will disregard any votes cast in favour of these resolutions by or on behalf of a person who will obtain a material benefit as a
result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity).
However, this does not apply to a vote cast in favour of these resolutions by:
(a)
a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or
attorney to vote on the resolution in that way; or
(b)
the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given
to the chair to vote on the resolution as the chair decides; or
4
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate
of a person excluded from voting, on the resolution; and
(ii)
the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Resolution 4
The Company will disregard any votes cast in favour of Resolution 4 by or on behalf of Peak Asset Management Pty Ltd (and/or their
nominee(s)) or a person who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a
holder of ordinary securities in the entity) or an associate of that person (or those persons).
However, this does not apply to a vote cast in favour of this Resolution by:
(a)
a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or
attorney to vote on this Resolution in that way; or
(b)
the chair as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the chair to
vote on this Resolution as the chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
8.
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate
of a person excluded from voting, on this Resolution; and
(ii)
the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Enquiries
Shareholders are invited to contact the Company Secretary on 1300 384 692 or by email at melanie.leydin@vistra.com if they have any
queries in respect of the matters set out in these documents.
5
EXPLANATORY STATEMENT
This Explanatory Statement forms part of the Company’s Notice of Extraordinary General Meeting and is intended
to assist Shareholders in consideration of the business proposed at the Meeting.
Background to Resolutions 1 to 4
On 8 September 2025, the Company announced a two-tranche placement to raise $2.5 million (before costs) from
professional and sophisticated investors (Placement Participants) (Placement). The placement comprises two
tranches:
-
Tranche 1: Placement of 46,800,000 Shares utilising the Company’s existing placement capacity under Listing
Rules 7.1 and 7.1A. Resolution 1 seeks to ratify this prior issue of Shares (Tranche 1 Placement).
-
Tranche 2: The issue of 138,385,185 shares, conditional upon the Company obtaining shareholder approval
as being sought under Resolution 2 (Tranche 2 Placement).
The issue price of Shares under both tranches is $0.0135 (1.35 cents) per Share, with 1:1 free attaching Option
exercisable at $0.02 (2 cents), expiring 23 October 2027. The issue of the free attaching Options is subject to
shareholder approval as being sought under Resolution 3.
The Company engaged the services of Peak Asset Management Pty Ltd (Peak) to manage the Placement.
Pursuant to the mandate between the Company and Peak, the Company agreed subject to obtaining shareholder
approval and the Company raising $1.5 million under the Placement, to issue to Peak or its nominee, 35,000,000
Options (Lead Manager Options) as partial consideration for their capital raising and corporate advisory services
performed with respect to the Placement. The Lead Manager Options are subject to shareholder approval as being
sought under Resolution 4.
The funds raised under the Placement will provide the Company with working capital to support inventory growth,
streamline operations, and deliver its strategy of simplifying the business (including SKU rationalisation), shifting
to higher margin channels. The proposed uses of funds are indicative only and will be subject to modification on
an ongoing basis depending on the results obtained from the Company's activities and other factors relevant to the
Board's discretion as to usage of funding.
The offer of Options under the Placement and the Lead Manager Options will all be offered under a prospectus in
accordance with section 713 of the Corporations Act, which is expected to be lodged with ASIC on or around 2
October 2025 (Prospectus).
The terms and conditions of the Options proposed to be issued under the Placement and the Lead Manager
Options are the same and are detailed in Annexure 1.
Refer to the Company's ASX announcements on, and after, 2 October 2025 (including the Prospectus) for further
information in relation to the Options.
To the extent any of the Resolutions are not passed, subject to compliance with applicable laws and the Listing
Rules, the Board reserves its discretion to issue securities the subject of such Resolutions, including pursuant to
the Company's placement capacities available at the time under Listing Rule 7.1 and/or 7.1A. The Board also
reserves its discretion to utilise those placement capacities for other purposes, as permitted by the Listing Rules.
Resolution 1: Ratification of Prior Issue of Tranche 1 Placement Shares
Background
As noted above, the Company is seeking Shareholder approval pursuant to ASX Listing Rule 7.4 to ratify the issue
of 46,800,000 fully paid ordinary shares in the Company issued on 12 September 2025 at an issue price of $0.0135
(1.35 cents) per Share on the terms as announced on 8 September 2025.
The Shares were issued without Shareholder approval out of the Company’s existing placement capacity under
ASX Listing Rules 7.1 and 7.1A.
ASX Listing Rules
ASX Listing Rules 7.1 allows the Company to issue new securities up to 15% of the existing capital of the Company
in any 12-month period without the prior approval of Shareholders, excluding any security issues that meet the
requirements of one of the exceptions of ASX Listing Rule 7.2. The issue of 24,650,000 Shares to Placement
Participants was within the Company’s available placement capacity under ASX Rule 7.1 and did not fit within any
of the Listing Rule 7.2 exceptions.
6
ASX Listing Rule 7.1A enables eligible entities which have obtained shareholder approval by special resolution to
issue securities up to the equivalent of 10% of the Company’s fully paid ordinary issued capital for cash
consideration a 12-month period after the Annual General Meeting (10% Placement Facility). The 10% Placement
Facility is in addition to the Company’s 15% placement capacity under ASX Listing Rule 7.1. The Company
obtained such shareholder approval for the 10% Placement Facility at the Annual General meeting held on 20 May
2025. The issue of 22,150,000 Shares to Placement Participants was within the Company’s available placement
capacity under ASX Listing Rule 7.1A and did not fit within any of the Listing Rule 7.2 exceptions.
Under ASX Listing Rule 7.4 an issue of securities will be treated as having been made with the approval of
Shareholders for the purposes of ASX Listing Rule 7.1 if the issue did not breach ASX Listing Rule 7.1 at the time
and Shareholders subsequently approve it. As the issue of the Shares was within the Company's ASX Listing Rule
7.1 and 7.1A placement capacity, did not fall within any of the exceptions in ASX Listing Rule 7.2, and was not
previously approved by Shareholders, the Company now seeks ratification of the issue of these Shares pursuant
to ASX Listing Rule 7.4 so as to refresh its capacity to make further issues (if required) without Shareholder
approval under Listing Rules 7.1.
If Resolution 1 is approved, the prior issue of 46,800,000 Shares may be treated by the Company as having been
made with Shareholder approval under ASX Listing Rule 7.1. The Company will therefore have the flexibility, if
required, to issue additional equity securities without the 46,800,000 Shares counting towards the 15% threshold
for the purposes of ASX Listing Rules 7.1 or the 10% threshold for the purposes of ASX Listing Rule 7.1A.
If Resolution 1 is not approved, the prior issue of 46,800,000 Shares will not be treated by the Company as having
been made with Shareholder approval under ASX Listing Rules 7.1. The Company will therefore have 24,650,000
Shares as counting towards the 15% threshold for the purposes of ASX Listing Rule 7.1 and 22,150,000 Shares
as counting towards the 10% threshold for the purposes of ASX Listing Rule 7.1A.
ASX Listing Rule Disclosure Requirements
ASX Listing Rule 7.5 requires that the following information be provided to Shareholders for the purpose of
obtaining Shareholder approval pursuant to ASX Listing Rule 7.4:
(a) the Shares were issued to professional and sophisticated investors, who are not related parties, identified by
the book build conducted by the Lead Manager, Peak Asset Management Pty Ltd. There were no participants
in the placement that were investors required to be disclosed under ASX Guidance Note 21;
(b) the number and class of securities issued was 46,800,000 fully paid ordinary shares in the Company, issued
on the same terms and conditions as the Company’s existing Shares;
(c) the Shares were issued on 12 September 2025;
(d) the Shares were issued for cash, at an issue price of $0.0135 (1.35 cents) per Share;
(e) the Shares were not issued under an agreement; and
(f)
the purpose of the issue was to raise funds to provide the Company with working capital to support inventory
growth, streamline operations, and deliver its strategy of simplifying the business (including SKU
rationalisation), shifting to higher margin channels.
Board Recommendation
The Board recommends that Shareholders vote in favour of the resolution.
The Chair of the Meeting intends to vote undirected proxies in favour of Resolution 1.
Voting Exclusions
Refer to Note 7 for voting exclusions.
Resolution 2: Approval to issue Tranche 2 Placement Shares
Background
Resolution 2 seeks Shareholder approval for the purpose of Listing Rule 7.1 and all other purposes for the issue
7
of 138,385,185 Shares in the Company at an issue price of $0.0135 (1.35 cents) per Share to professional and
sophisticated investors in relation to the Tranche 2 Placement as announced on 8 September 2025.
ASX Listing Rules
Listing Rule 7.1 provides that, subject to certain exceptions, prior approval of shareholders is required for an issue
of securities by a company if those securities, when aggregated with the securities issued by the company during
the previous twelve (12) months (without approval and which were not subject to an exception), exceed fifteen
percent (15%) of the number of shares on issue at the commencement of that twelve (12) month period.
The proposed issue of Shares does not fall within any of the exceptions in Listing Rule 7.1. The Company is now
seeking Shareholder approval for the issue of Tranche 2 Placement Shares to the Placement participants.
If Resolution 2 is approved by Shareholders, the Company will be able to proceed with the issue of Shares during
the period of three (3) months after the Meeting or a longer period, if allowed by ASX. In addition, the issue of the
Shares will be excluded from calculating the Company’s fifteen percent (15%) limit in Listing Rule 7.1 and the
Company will retain the flexibility to issue securities in the future up to the fifteen percent (15%) placement capacity
set out in ASX Listing Rule 7.1 without the requirement to obtain prior Shareholder approval.
If Resolution 2 is not approved by Shareholders, the Company would not be able to proceed with the issue of
138,385,185 Shares without Shareholder approval.
ASX Listing Rule Disclosure Requirements
The following information is provided to satisfy the requirements of ASX Listing Rule 7.3:
(a) the Shares will be issued to the professional and sophisticated investors under the Placement (or their
nominees(s));
(b) the number and class of securities being issued is up to 138,385,185 fully paid ordinary shares in the
Company, to be issued on the same terms and conditions as the Company’s existing Shares;
(c) the Shares will be issued by no later than three months after the date of this Meeting, however, are expected
to be issued on or around 4 November 2025;
(d) the Shares will be issued at an issue price of $0.0135 (1.35 cents) per Share;
(e) the Shares are not being issued under an agreement; and
(f)
the purpose of the issue is to raise funds to provide the Company with working capital to support inventory
growth, streamline operations, and deliver its strategy of simplifying the business (including SKU
rationalisation),
Board Recommendation
The Board recommends that Shareholders vote in favour of Resolution 2.
The Chair of the Meeting intends to vote undirected proxies in favour of this Resolution.
Voting Exclusions
Refer to Note 7 for voting exclusions.
Resolution 3: Approval to issue attaching options to Placement participants
Resolution 3 seeks Shareholder approval for the purpose of Listing Rule 7.1 and all other purposes for the issue
of up to 185,185,185 free attaching options, exercisable at $0.02 (2 cents) and expiring 23 October 2027 (Options)
to sophisticated and professional investors as part of the Placement announced by the Company on 8 September
2025.
The Options are to be offered under the Prospectus. Refer to the Company's ASX announcements dated on and
after 2 October 2025 for further details.
Refer to Annexure 1 for the detailed terms of the Options.
8
ASX Listing Rules
Listing Rule 7.1 provides that, subject to certain exceptions, prior approval of shareholders is required for an issue
of securities by a company if those securities, when aggregated with the securities issued by the company during
the previous twelve (12) months (without approval and which were not subject to an exception), exceed fifteen
percent (15%) of the number of shares on issue at the commencement of that twelve (12) month period.
The proposed issue of Options does not fall within any of the exceptions in Listing Rule 7.1. The Company has
however chosen to seek Shareholder approval for the issue of Options to the Placement participants and not use
the capacity under ASX Listing Rule 7.1.
If Resolution 3 is approved by Shareholders, the Company will be able to proceed with the issue of Listed Options
during the period of three (3) months after the Meeting or a longer period, if allowed by ASX. In addition, the issue
of the Listed Options will be excluded from calculating the Company’s fifteen percent (15%) limit in Listing Rule 7.1
and the Company will retain the flexibility to issue securities in the future up to the fifteen percent (15%) placement
capacity set out in ASX Listing Rule 7.1 without the requirement to obtain prior Shareholder approval.
If Resolution 3 is not approved by Shareholders, the Company would not be able to proceed with the issue of up
to 185,185,185 Listed Options. If the Company is unable to proceed with the issue it may be required to re-negotiate
the terms of the Placement with the participants.
ASX Listing Rule Disclosure Requirements
The following information is provided to satisfy the requirements of ASX Listing Rule 7.3:
(a) the Options will be issued to sophisticated and professional investors under Placement (or their nominees(s));
(b) the number and class of securities being issued is up to 185,1
Share your feedback
Discover